samedan logo
 
 
 
spacer
home > ebr > autumn 2017 > definitive screening designs
PUBLICATIONS
European Biopharmaceutical Review

Definitive Screening Designs

The ability to quickly develop reliable and robust analytical test methods is an important aspect of navigating the technical path to a successful investigational new drug (IND) submission. Often, an insufficient amount of time is allocated to understanding analytical methods and reference materials and how they perform at in-process test points.

Charge Heterogeneity

Analytical comprehension is particularly challenging for proteins expressed in mammalian cells, which can present extensive charge heterogeneity resulting from variations in post-translational modifications (PTMs). The milieu parameters in any given bioprocess can impact charge heterogeneity, which, when not properly understood and controlled, can cause unwanted batch-to-batch variation in product quality.

Therefore, early detection of charge heterogeneity, using a robust method with good resolution, is an important capability for process development. Some PTMs result in charge differences on the molecule that are likely to alter the protein’s stability or activity.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Srividya Suryanarayana has over five years’ industry experience at Cytovance Biologics and over seven years’ academic experience in R&D. She is a subject matter expert on charge-based analytical methods using icIEF and has a strong background in enzymology, protein biochemistry, analytical method development, qualification and validation. Srividya is a method validation lead scientist in Quality Control at Cytovance Biologics, leading method validation activities for several client-specific projects. She holds a PhD in biochemistry/biophysics from the University of Kansas, US, and has completed post-doctoral training from the Medical College of Wisconsin, US.
spacer
Dr Srividya Suryanarayana
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Bio-Rad Launches Its CFX Opus Dx Real-Time PCR Detection Systems for In Vitro Diagnostics

HERCULES, Calif.–October 21, 2021–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the CFX™ Opus 96 Dx System and the CFX™ Opus 384 Dx System
More info >>

White Papers

Changing Structural Landscape for Comparator Drug Supply

ADAllen Pharma

TransCelerate Biopharma is focused on advancing innovation in R&D, identifying and solving common R&D challenges and further improving patient safety, with the goal of delivering more high quality medicines to patients. In 2013, they announced its Clinical Trial Comparator Network initiative to show a mutual commitment to offer secure and rapid supply of comparator drug products. The aim of this article is to unpack the section on 'Comparator Drugs' and analyse the rationale for attempting to achieve their objectives.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement